Publicaciones en colaboración con investigadores/as de Hospital Universitario de Jaén (26)

2023

  1. Spanish cardiac catheterization and coronary intervention registry. 32nd official report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2022)

    Revista Espanola de Cardiologia, Vol. 76, Núm. 12, pp. 1021-1031

2022

  1. Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia

    Cancers, Vol. 14, Núm. 11

  2. Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics

    BMC Cancer, Vol. 22, Núm. 1

2021

  1. Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 6, pp. 413-420

  2. Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data

    BMC Cancer, Vol. 21, Núm. 1

  3. Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. Association of a single nucleotide polymorphism combination pattern of the Klotho gene with non-cardiovascular death in patients with chronic kidney disease

    Clinical Kidney Journal, Vol. 13, Núm. 6, pp. 1017-1024

  2. Impact of COVID-19 on ST-segment elevation myocardial infarction care. The Spanish experience

    Revista Espanola de Cardiologia, Vol. 73, Núm. 12, pp. 994-1002

  3. Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation

    Cancer Epidemiology, Vol. 67

2019

  1. A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients

    Leukemia Research, Vol. 76, pp. 1-10

  2. Association of candidate gene polymorphisms with chronic kidney disease: Results of a case-control analysis in the NEFRONA cohort

    Frontiers in Genetics, Vol. 10, Núm. FEB

  3. Lung cancer in Spain: Information from the Thoracic Tumors Registry (TTR study)

    Translational Lung Cancer Research, Vol. 8, Núm. 4, pp. 461-475

  4. Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial

    Cancer Medicine, Vol. 8, Núm. 16, pp. 6955-6966

2018

  1. Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice

    Clinical and Translational Oncology, Vol. 20, Núm. 7, pp. 862-869

2017

  1. Factors influencing pathological ankle-brachial index values along the chronic kidney disease spectrum: The NEFRONA study

    Nephrology Dialysis Transplantation, Vol. 32, Núm. 3, pp. 513-520

2015

  1. Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease

    Nephrology Dialysis Transplantation, Vol. 30, Núm. 7, pp. 1176-1185

2014

  1. Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: A bridge to individualized medicine

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 14, Núm. 4, pp. 305-318

2013

  1. Casos autodeclarados de síndrome gripal en trabajadores sanitarios españoles durante la pandemia de gripe A (H1N1) 2009

    Gaceta Sanitaria, Vol. 27, Núm. 2, pp. 167-170

2011

  1. Evaluation of tolerability and efficacy of imatinib mesylate in elderly patients with chronic phase CML: ELDERGLI study

    Leukemia Research, Vol. 35, Núm. 9, pp. 1184-1187

  2. Hormone-responsive breast cancer

    Advances in Therapy, Vol. 28, Núm. 12, pp. 1045-1058